UNSPSC 51373410: Ammonium/bromodiphenhydramine/codeine/diphenhydramine/potassium

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373410 Ammonium/bromodiphenhydramine/codeine/diphenhydramine/potassium is a Commodity code covering pharmaceutical products, including controlled substances, that state and local government health and public-safety agencies procure for patient care and emergency response. The code captures both routine pharmaceutical inventory (parenteral solutions, intravenous preparations, naloxone) and specialized medical-delivery systems. Issuing bodies include state departments of corrections, county health departments, and county emergency management offices procuring these products for incarcerated populations, community health initiatives, and opioid-overdose response. Scope of work spans parenteral nutrition solutions (TPN and PPN), intravenous fluids, naloxone auto-injectors, and drug deactivation systems, with service-level requirements such as rapid preparation and delivery (24-hour turnaround for specialized preparations), patient monitoring, and formulation adjustments where medically indicated.

Recent activity appears concentrated in the Pacific Northwest and Southeast. The Washington State Department of Corrections issued RFQQK13020 on September 8, 2026, requesting quotes for parenteral products and services to supply eight correctional facilities across three regions, with a response deadline of October 7, 2026 and awards anticipated to three bidders per region; the contract runs November 26, 2026 through June 30, 2030 with fixed pricing for the initial two-year term and pre-bid conference scheduled September 23, 2026. Seminole County, Florida issued IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, though the response deadline listed in the source (July 26, 2023) appears to be a date error. Both opportunities require proof of business licensure, insurance coverage (Commercial General Liability, Professional Liability, Business Automobile Liability, and Cyber Liability), and E-Verify compliance. Washington's solicitation includes set-aside aspirations for small businesses (25%), minority-owned businesses (10%), women-owned businesses (6%), and veteran-owned businesses (5%).